公开(公告)号：US20190183979A1

公开(公告)日：2019-06-20

申请号：US16280603

申请日：2019-02-20

申请人： Novo Nordisk A/S

发明人： Mathias Norrman ,  Susanne Hostrup ,  Dorte Bjerre Steensgaard ,  Holger Martin Strauss ,  Rosa Rebecca Erritzoee Hansen ,  Svend Havelund ,  Morten Schlein ,  Jesper Soendergaard Pedersen

IPC分类号： A61K38/28 ,  A61K47/02 ,  A61K47/10 ,  A61P5/48

摘要： The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.

公开(公告)号：US20180303908A1

公开(公告)日：2018-10-25

申请号：US16023328

申请日：2018-06-29

申请人： Novo Nordisk A/S

发明人： Mathias Norrman ,  Susanne Hostrup ,  Dorte Bjerre Steensgaard ,  Holger Martin Strauss ,  Rosa Rebecca Erritzoee Hansen, Hansen ,  Svend Havelund ,  Morten Schlein ,  Jesper Soendergaard Pedersen

IPC分类号： A61K38/28 ,  A61K47/10 ,  A61P5/48 ,  A61K47/02

CPC分类号： A61K38/28 ,  A61K47/02 ,  A61K47/10 ,  A61P5/48

摘要： The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.

公开(公告)号：US20220202909A1

公开(公告)日：2022-06-30

申请号：US17692238

申请日：2022-03-11

申请人： Novo Nordisk A/S

发明人： Mathias Norrman ,  Susanne Hostrup ,  Dorte Bjerre Steensgaard ,  Holger Martin Strauss ,  Rosa Rebecca Erritzoee Hansen ,  Svend Havelund ,  Morten Schlein ,  Jesper Soendergaard Pedersen

IPC分类号： A61K38/28 ,  A61P5/48 ,  A61K47/02 ,  A61K47/10

摘要： The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.

公开(公告)号：US10596231B2

公开(公告)日：2020-03-24

申请号：US16280603

申请日：2019-02-20

申请人： Novo Nordisk A/S

发明人： Mathias Norrman ,  Susanne Hostrup ,  Dorte Bjerre Steensgaard ,  Holger Martin Strauss ,  Rosa Rebecca Erritzoee Hansen ,  Svend Havelund ,  Morten Schlein ,  Jesper Soendergaard Pedersen

IPC分类号： A61K38/28 ,  A61P5/48 ,  A61K47/02 ,  A61K47/10

摘要： The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.

公开(公告)号：US10265385B2

公开(公告)日：2019-04-23

申请号：US16023328

申请日：2018-06-29

申请人： Novo Nordisk A/S

发明人： Mathias Norrman ,  Susanne Hostrup ,  Dorte Bjerre Steensgaard ,  Holger Martin Strauss ,  Rosa Rebecca Erritzoee Hansen ,  Svend Havelund ,  Morten Schlein ,  Jesper Soendergaard Pedersen

IPC分类号： A61K38/28 ,  A61P5/48 ,  A61K47/02 ,  A61K47/10

摘要： The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analog, and to the medical use of such compositions for basal insulin administration therapy.

公开(公告)号：US20180169190A1

公开(公告)日：2018-06-21

申请号：US15843016

申请日：2017-12-15

申请人： Novo Nordisk A/S

发明人： Mathias Norrman ,  Susanne Hostrup ,  Dorte Bjerre Steensgaard ,  Holger Martin Strauss ,  Rosa Rebecca Erritzoee Hansen ,  Svend Havelund ,  Morten Schlein ,  Jesper Soendergaard Pedersen

IPC分类号： A61K38/28 ,  A61K47/10 ,  A61P5/48 ,  A61K47/02

摘要： The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.